Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

@article{Maubec2011PhaseIS,
  title={Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.},
  author={E. Maubec and P. Petrow and Isabelle Scheer-Senyarich and P. Duvillard and L. Lacroix and J. Gelly and A. Certain and X. Duval and B. Crickx and V. Buffard and N. Basset-Seguin and Pierre Saez and A. Duval-Modeste and H. Adamski and S. Mansard and F. Grange and A. Dompmartin and S. Faivre and F. Mentr{\'e} and M. Avril},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 25},
  pages={
          3419-26
        }
}
  • E. Maubec, P. Petrow, +17 authors M. Avril
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS). [...] Key MethodPATIENTS AND METHODS Thirty-six patients received cetuximab (initial dose of 400 mg/m(2) followed by subsequent weekly doses of 250 mg/m(2)) for at least 6 weeks with a 48-week follow-up.Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to determine whether cetuximab is effective in the treatment of locally advanced or metastatic squamous cell carcinoma of the skin expressing EGFR.  
ConditionsCarcinoma, Squamous Cell, Skin Diseases
InterventionDrug
Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).
  • J. Grob, R. Gonzalez, +11 authors B. Hughes
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2020
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin.
  • B. Glisson, E. Kim, +7 authors S. Lippman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
  • D. Shin, B. Glisson, +12 authors S. Lippman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5‐fluorouracil, and bleomycin
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
...
1
2
3
4
5
...